Get the Stockscreener App
4.14
4.54%
0.1799
Intensity Therapeutics Inc stock is traded at $4.14, with a volume of 19,399.
It is up +4.54% in the last 24 hours and down -12.84% over the past month.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
See More
Previous Close:
$3.9601
Open:
$3.96
24h Volume:
19,399
Relative Volume:
0.49
Market Cap:
$13.51M
Revenue:
-
Net Income/Loss:
$-10.69M
P/E Ratio:
-0.5846
EPS:
-7.0818
Net Cash Flow:
$-9.07M
1W Performance:
-3.50%
1M Performance:
-12.84%
6M Performance:
-25.87%
1Y Performance:
-43.81%
1-Day Range:
$3.94
$4.1688
1-Week Range:
$3.9008
$4.35
52-Week Range:
$3.51
$43.50
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
4.1375 | 12.93M | 0 | -10.69M | -9.07M | -7.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.22 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.16 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript - aol.com
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Intensity Therapeutics Warns of Substantial Doubt - Minichart
Intensity Therapeutics Q2 Results: EPS loss narrows 67% YoY - scanx.trade
INTS: Q2 2026 saw higher R&D spend, resumed trial enrollment, and strong early TNBC efficacy data - TradingView
Transcript : Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
INTS: Net loss rose 19% to $3M as clinical trials resumed, with $9.5M cash and $30M more needed for completion - TradingView
Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket - Investing.com
Intensity Therapeutics (INTS) Advances Clinical Trials Amidst Ch - GuruFocus
Intensity Therapeutics Reports $3.0 Million Q2 Net Loss - Quiver Quantitative
Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment - TradingView
Intensity Therapeutics Q2 net loss widens as R&D costs rise - TradingView
INTS: Resumed clinical trial enrollment and raised capital, with improved early TNBC study results - TradingView
BRIEF-Intensity Therapeutics Q2 Operating Income USD -3.084 Million - TradingView
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary - TradingView
INTS Q2'26 Earnings: EPS estimate is (0.87) USD - TradingView
BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million - TradingView
Intensity Therapeutics (INTS.US) will release its earnings report on August 11. - Moomoo
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intensity Therapeutics Inc (INTS) Stock News Today - TradingKey
Intensity Therapeutics (INTS.US) will release its earnings report before the market opens on August 11. - Moomoo
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 - Yahoo Finance
INTS Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INTS|Intensity Therapeutics Inc|Price:4.570|Chg%:+0.120 - TradingKey
INTS|Intensity Therapeutics Inc|Price:3.960|Chg%:-0.040 - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Balance Sheet - TradingKey
Intensity Therapeutics Inc (INTS) Income Statement - TradingKey
Intensity Therapeutics Inc (INTS) Cash Flow - TradingKey
INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030 - TradingKey
INTS Stock Price, Quote & Chart - ChartMill
Intensity Therapeutics (INTS) Proxy filing Summary - Quartr
Intensity Therapeutics (INTS) Q1 2026 earnings summary - Quartr
Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS) - Stock Titan
Intensity Therapeutics (INTS) awards director 5,500 options at $4.90 strike - Stock Titan
Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading - Stock Titan
Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90 - Stock Titan
Intensity Therapeutics (INTS) grants 11,000 stock options to accounting officer - Stock Titan
Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90 - Stock Titan
Intensity Therapeutics grants 78,000 options to CEO | INTS Insider Trading - Stock Titan
Intensity Therapeutics Restarts Phase 2 TNBC Trial - t.co
Intensity Therapeutics (INTS) Edges Higher, Holding Above Key Support at $4.66Fear Greed Extreme - dars.gov.et
New patients dosed with INT230-6 in Swiss trial for aggressive triple-negative breast cancer - Pluang
Intensity Therapeutics (INTS) AGM 2026 Summary - Quartr
Intensity Therapeutics (INTS) Q4 2025 earnings summary - Quartr
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):